An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, ...

Belgium: A phase 2 international trial published in The Lancet has found that low-dose antithymocyte globulin (ATG) can slow ...

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of ...

Investigators have identified the lowest dose of the immunosuppressive ATG needed to preserve beta cells in newly diagnosed children with Type 1 diabetes with the lowest side effects.

Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D), ...

Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

Type 2 diabetes medications, such as sulfonylureas, have been a mainstay of treating the disease since they came on the ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

ZyVersa Therapeutics (ZVSA) highlights data from an article published in the peer-reviewed International Journal of Nanomedicine titled Small Intestinal Endocrine Cell Derived Exosomal ACE2 Protects ...

For years, the pancreas has been being taught in biology class as an easy system: insulin lowers blood sugar, and glucagon ...